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Objective: To investigate the expression and the regulation effect of cell growth of
microRNA-577 in hepatocellular carcinoma (HCC).
Methods: qRT-PCR was applied to detect the relative expression of miR-577 in 70
paired HCC and matched tumor adjacent tissues collecting from resection between March
2011 and March 2014. Pearson chi-square test was used to analyze the relationship be-
tween the miR-577 expression and clinical features. The miR-577 mimics were trans-
fected into HepG2 cells; cell cycles were detected by ﬂow cytometry, cell proliferation
was measured by MTT assay and BrdU incorporation assay, and cell apoptosis was
determined by ﬂow cytometry and caspase3/7 activity analysis. The expressions of b-
catenin were measured by immunohistochemistry. Spearman correlation analysis was
used to analyze the relationship between miR-577 and b-catenin. qRT-PCR and western-
blot were used to detect the expression of b-catenin in transfected HepG2 cells.
Results: The relative expressions of miR-577 was signiﬁcantly lower in HCC tissues
compared to the matched normal tumor-adjacent tissues (P < 0.05). Low expression of
miR-577 was signiﬁcantly associated with large tumor size (5 cm, P < 0.05) and
advanced tumor node metastasis stage (III+IV, P < 0.05). Transfection of miR-577
mimics could inhibit repress cell proliferation, enhance cell apoptosis and block the
cell cycles in G0/G1 phase (P < 0.05). miR-577 in HCC group had a signiﬁcant negative
correlation relationship with the expression of downstream target of b-catenin (P < 0.05).
Both the mRNA and protein expression in HepG2 cells were down-regulated after
transfection (P < 0.05).
Conclusions: Low expression of miR-577 is related to the malignant clinicopathological
features in HCC tissues, and miR-577 may suppress HCC growth through down-
regulating b-catenin.1. Introduction
Hepatocellular carcinoma (HCC), short for hepatic carci-
noma, is a kind of digestive system cancer with a high malignant
degree [1]. In recent years, the morbidity of HCC has been
constantly rising. Because of its insidious symptoms, rapid
development and difﬁculties in early diagnosis, most patients
are in the tumor advanced stage when they seek medicaltreatment. Molecular targeted drugs are mainly used in
advanced liver cancer including interventional embolization
treatment and oral administration of Sorafenib. However, the
reaction rate is low in the patients and the 5-year survival rate
is less than 20% [2]. Therefore, HCC has become one of the
important factors to endanger people's health.
microRNA is a kind of single non-coding RNA with the
length of about 19–25 nucleotides. Through the speciﬁcity of
complete or incomplete complementary combination with 30-
untranslated region of mRNA target, mRNA degradation can be
performed, and the role of the translation process can be
inhibited [3]. Studies have shown that the abnormal expressions
of a variety of miRNA exist in HCC tissues. For example, the
expressions of miR-21 increase in HCC tissue and are closely
related with HCC clinical stages as well as poor prognosis; alson access article under the CC BY-NC-ND
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antiapoptotic effect through down-regulating apoptosis related
proteins PDCD4 and Fas-L [4,5]. miR-218 with a high biological
activity can promote the proliferate ability of HCC cells through
degrading CDK6 and BMI-1 [6]. miR-577 has regulating effect
on the occurrence and development of many malignant tumors,
which has down-regulated expression and even deﬁciency in a
variety of human malignant tumors. At the same time miR-577
is closely related many biological actions including tumor pro-
liferation and apoptosis [7]. Through bioinformatics search, it is
found that b-catenin is one of the downstream potential targets
for miR-577, which is the CTNNB1 gene coding located in the
chromosome 3p21. b-catenin is one of the key molecular in
Wnt/b-catenin signaling pathway. Clinical trial results of II
phrase show that imatinib mesylate can interfere Wnt/b-catenin
signaling pathway and prevent tumor metastasis, which obtain
better efﬁciency in the treatment of Philadelphia chromosome
positive leukemia [8]. Other experimental targeted drugs that
aimed at Wnt/b-catenin such as M475271 [9], AZD0530 [10],
and Bosutinib [11] have also obtained certain results in
decreasing tumor metastasis like prostatic cancer and breast
cancer. Therefore, b-catenin has important research value in
tumor biological treatment. Currently, clinical pathological
signiﬁcance and speciﬁc molecular mechanism of miR-577 in
HCC is still unclear. The present study investigated the clinical
signiﬁcance and action mechanism of miR-577 in the occurrence
and development of HCC through studying the expressions of
miR-577 in HCC and matched tumor adjacent tissues, its bio-
logical function and its regulating effect of potential b-catenin
target. The study can provide a new molecular target for the
diagnosis and treatment of HCC.
2. Materials and methods
2.1. Clinical specimens
The present study was performed after the approval of the
medical ethics committee of our study. A total of 70 cases of
HCC as well as matched tumor adjacent tissues were collected
from March 2011 to March 2014 that were performed surgical
excision and conﬁrmed with pathology. Among them, 49 were
males and 21 were females aging 42–74 years [average age
(55.7 ± 1.6) years]. All the specimens were in vitro materials
stored in liquid nitrogen or neutral formalin solution.
2.2. qRT-PCR
microRNA and mRNA were extracted from the tissue or cell
according to the method of the TRIZOL reagent instruction.
cDNA was compounded through reverse transcription, and then
2 mL cDNA was taken for ampliﬁcation detection by real-time
PCR. RNU6B gene was regarded as the internal reference of
microRNA detection, and b-actin gene was regarded as the in-
ternal reference of mRNA detection. 2−DDCt method was used to
calculate the quantity of relative expression.
2.3. Cell culture
Immortalized human hepatocyte cell line LO2 and HCC
including HepG2, Hep3B, SMMC-7721, Bel-7402 and Huh7
were stored in our laboratory. All the cells were cultured insuitable environment, and further experiment was performed
after stable passage of 2–3 generations.
2.4. Cell transfection
HepG2 cells were cultured in 6-well plate to about 50% of
fusion degrees and underwent intervention. Experimental group
(per well): 100 pmoL miR-577 mimics & 5 mL Lipofectamine™
2000; Control group (per well): 100 pmoL NC mimics & 5 mL
Lipofectamine™ 2000. After incubation with serum-free me-
dium for 6–8 h, the complete medium was changed for further
culture.
2.5. MTT test
HepG2 cells transfected for 0, 24, 48, and 72 h respectively
were collected and incubated in 96-well plate. After incubated to
cell adherence in the incubator, MTT reagent was added and
cultured for 4 h. The supernatant was discarded and DMSO was
added to dissolve the crystals. ELIASA was used to detect the
absorbance value at OD 490 nm.
2.6. BrdU analysis
The transfected miR-577 mimics of HepG2 were incubated
in 96-well plate; then BrdU solution was added to incubate for
24 h and ﬁxed by adding stationary liquid. Antigen-antibody
method was used to detect the BrdU synthesis.
2.7. Cell cycle and cell apoptosis detection
HepG2 cells transfected for 72 h were taken to detect the cell
cycle by PI simple staining and to detect cell apoptosis by
Annexin Ⅴ-FITC as well as PI simple staining.
2.8. Detection of HepG2 cell apoptosis by Caspase3/7
activity analysis
HepG2 cells transfected for 72 h were incubated in 96-well
plate and three blank wells were set up. Caspase3/7 intracellular
activity was detected by Apo-ONE® Caspase-3/7 Assay Kit, and
Cell ﬂuorescence intensity at 499 nm was measured by ELISA
Tablet counter for quantitative assessment.
2.9. Immunohistochemistry
The tissue sample was produced routinely to 4 mm parafﬁn
section. Rabbit anti-human b-catenin anti-body (1:100) was used
to detect b-catenin protein expression of the issue. Each section
was read and graded independently by the two high qualiﬁcation
pathologists in the case of double blind [12].
2.10. Western blot
Total protein of HepG2 cells transfected for 72 h was
extracted and the concentration was detected. About 50 mg
protein sample was added in each well and isolated with 10%
SDS-PAGE gel electrophoresis. BIO-RAD Trans-Blot SD was
used for transmembrane, primary antibody of b-catenin (1:1000)
and primary antibody of b-actin was used to detect the protein
expression.
Table 1
Relationship between miR-577 expression and clinicopathologic feature
of HCC patients (n = 70).
Clinicopathologic
features
Classiﬁcation miR-577
expression
P
Age >50 years of age 2.609 ± 0.101 0.098
50 years of age 2.281 ± 0.134
Sex Male 2.434 ± 0.191 0.133
Female 2.229 ± 0.107
HBsAg Positive 2.629 ± 0.131 0.714
Negative 2.332 ± 0.135
Liver cirrhosis Yes 2.507 ± 0.132 0.081
No 2.213 ± 0.084
AFP 400 ng/mL 2.483 ± 0.011 0.873
<400 ng/mL 2.403 ± 0.097
Tumor volume <5 cm 4.791 ± 0.141 0.003**
5 cm 1.137 ± 0.119
Tumor number >1 2.284 ± 0.132 0.121
1 2.461 ± 0.117
Blood vessel
inﬁltration
No 2.531 ± 0.112 0.076
Yes 2.294 ± 0.170
Edmondson grading I+II 2.496 ± 0.092 0.595
III+IV 2.151 ± 0.101
TNM periodization I+II 3.546 ± 0.111 0.006**
III+IV 1.049 ± 0.136
**P < 0.01.
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Data were analyzed by SPSS13.0 software. Pearson Chi-
square test was used to analyze the enumeration data, and
mean ± sd was used to express the measurement data. t-test or
ANOVA was used for the comparison among groups. Pearson
correlation test was used to analyze the expression correlations
between miR-577 and b-catenin. P < 0.05 was considered as
statistical signiﬁcant difference.
3. Results
3.1. Relative expression of miR-577 in HCC and
matched tumor adjacent tissues
Through the detection of qRT-PCR technique, the relative
expression of miR-577 of HCC tissues in 70 cases was
2.402 ± 0.143 while that of matched tumor adjacent tissues
was 5.868 ± 0.302. Among HCC tissues of 55 (84.29%) cases,
the relative expression of miR-577 was lower than that of the
matched tumor adjacent tissues. The statistical test showed
that the difference was statistical signiﬁcant (P < 0.001)
(Figure 1).
3.2. Correlations between expression level of miR-577
and clinicopathologic feature of HCC patients
In order to investigate the correlations between expression
level of miR-577 and clinicopathologic feature, 70 cases of HCC
patients were classiﬁed with clinicopathologic features including
age, sex, HBV infection or not, liver cirrhosis or not, serum AFP
level, tumor volume, tumor number, blood vessel inﬁltration or
not, histopathological grading, tumor node metastasis (TNM)
periodization, etc. Through student's t-test, it was found that the
expression of miR-577 in HCC tissues with larger volume
(5 cm) and higher TNM periodization decreased signiﬁcantly
(P < 0.01) (Table 1).Figure 1. Expression of miR-577 in HCC and matched tumor adjacent
tissues.3.3. Transfection of miR-577 mimics into HepG2
The results showed that expression of miR-577 could be
detected in all the cell lines, among which LO2 expression was
the highest, and that of HepG2 was the lowest (P < 0.01)
(Figure 2A). Then, HepG2 was selected to be the intervention
cell. miR-577 mimics were transfected into HepG2 transiently
using liposomes method. The results showed that the transfected
miR-577 mimics could increase the intracellular expression level
of miR-577 of HepG2 signiﬁcantly (P < 0.001) (Figure 2B).
3.4. Inhibition of overexpression of miR-577 on HepG2
cell proliferation
Figure 3A showed that compared with normal control group,
the transfected miR-577 mimics could decrease the HepG2 cell
viability signiﬁcantly (P < 0.01). Then, BrdU was mixed into
transfected cells, and through cellular immunoﬂuorescence
staining and ELIASA analysis detection, it was found that DNA
synthesis ability of HepG2 was signiﬁcantly reduced after the
miR-577 mimics transfection (P < 0.01) (Figure 3B). The result
indicated that cell proliferation was inhibited.
3.5. Effect of overexpression of miR-577 on the G0/G1
phase of HepG2
Figure 4 showed that compared with normal control group,
percentage of HepG2 after miR-577 mimics transfection in G0/
G1 phase was signiﬁcantly increased (P < 0.05), while the cell
percentage in S period was signiﬁcantly decreased (P < 0.05),
which indicated that miR-577 would block tumor cells at DNA
presynthesis stage.
3.6. Effect of miR-577 on HepG2 cell apoptosis
The results conﬁrmed that after transfection of miR-577
mimics for 72 h, apoptosis percentage of miR-577 group was
Figure 3. Effect of miR-577 on cell proliferation capacity of HepG2.
A: HepG2 cell viability (**P < 0.01); B: DNA synthesis of HepG2 (**P < 0.01).
Figure 2. Transfection of miR-577 mimics into HepG2.
A: Expression of miR-577 in different cell lines (**P < 0.01, *P < 0.05); B: After miR-577 mimics transfected into HepG2, expression level of miR-577 was
signiﬁcantly increased (**P < 0.01).
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(P < 0.01) (Figure 5A and B). Caspase3/7 activity analysis also
showed that related enzyme activity of HepG2 cell apoptosis
was statistically increased after miR-577 transfection (P < 0.01)
(Figure 5C). The results showed that miR-577 in vitro could
inhibit HepG2 cell proliferation and promote its apoptosis.
3.7. Correlation of protein expressions between miR-
577 and b-catenin in HCC tissues
Immunohistochemical results showed that the protein
expression intensity of b-catenin in miR-577 low expression
group was signiﬁcantly higher than that in miR-577 high
expression group (P < 0.05) (Figure 6A). Pearson correlation
analysis showed that there was a signiﬁcantly negative correla-
tion between miR-577 and b-catenin expression (P < 0.001)
(Figure 6B).
3.8. Effect of overexpression of miR-577 on expression
of b-catenin in HepG2
It was found that compared with control group, over-
expression of miR-577 down-regulated the expression levels of
b-catenin mRNA (Figure 7A) and protein (Figure 7B) signiﬁ-
cantly in HepG2 (P < 0.01).4. Discussion
HCC is common in the world and is one of the digestive
system malignant tumors with a high lethality rate. It has a
morbidity of 622000 people per year and a mortality rate of
600000 people per year [13]. The appearance of targeted drug
Sorafenib prolongs the survival time of HCC patients at
advanced stage effectively [14] and is also proved that
molecular targeting treatment plays an important role in
improving the prognosis of HCC patients. Therefore, searching
for new molecular targeted antitumor and exploring its
antitumor mechanism have been one of the key methods to
improve the therapeutic effect of patients as well as ameliorate
the prognosis of HCC patients.
HCC tissues exist a large number of microRNA abnormal
expressions and play an important effect in the occurrence and
development of HCC. For example, expressions of miR-218 in
HCC tissues and HCC cells reduced signiﬁcantly and in vitro
overexpression of miR-218 could inhibit proliferate ability of
HCC cells and induce apoptosis signiﬁcantly through down-
regulating the expression CDK6 and BMI-1 [15]. While the
expression of miR-27a in HCC tissues increased signiﬁcantly
compared with normal liver tissue and was closely related to
patients with poor prognosis; and overexpression of miR-27a in
HepG2 and Huh7 promoted the ability of cell proliferation,
Figure 4. Effect of miR-577 on HepG2 cell cycle.
*P < 0.05.
Figure 5. Effect of miR-577 on cell proliferation and apoptosis ability of HepG2.
A & B: Apoptosis percentage of HepG2 signiﬁcantly (**P < 0.01); C: Related enzyme activity of HepG2 cell apoptosis signiﬁcantly (**P < 0.01).
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conﬁrmed that the expression level of miR-577 in HCC tissues
was signiﬁcantly lower than that in matched tumor adjacent
tissues, and its low expression was closely related to malignant
clinicopathologic features such as the enlargement of tumor
volume and high TNM periodization. It is showed that miR-577
has important regulating effect in HCC progress.
As an important suppressor molecule, miR-577 can play a
role of antitumor through down-regulating the expression levels
of multiple oncogenes in tumor. Zhang et al found that miR-577
can down-regulate the expression of lipoprotein receptor relatedprotein 6, which is the key molecule of Wnt signaling pathway
to inhibit the growth of malignant brain glioma [17]. The study of
Yuan et al also showed that miR-577 down-regulates TSGA10
to achieve the goals of proliferation inhibition, apoptosis in-
duction and cell cycle arrest of esophageal squamous cells [18].
In the present study, miR-577 mimics were used for the over-
expression of miR-577 in HepG2, and it has been proved by
MTT and BrdU experiment that miR-577 can inhibit cell pro-
liferation through restraining HepG2 cell viability and DNA
synthesis. Cell cycle analysis showed that after the over-
expression of miR-577, cell counts in DNA replicative phase (S
Figure 6. Expression of b-catenin protein in HCC tissues and the correlation with miR-577.
A: Expressions of b-catenin protein in different miR-577 expression levels of HCC tissues (*P < 0.05); B: Correlation between miR-577 and b-catenin
expression.
Figure 7. Overexpression of miR-577 down-regulating the expression of b-catenin in HepG2.
A: Expression of b-catenin mRNA of HepG2 (**P < 0.01); B: Expression of b-catenin protein of HepG2.
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prophase of DNA synthesis namely G0/G1 phrase. It was found
in further study that the expression of miR-577 increased the
related enzyme activities of cell apoptosis signiﬁcantly. The
result of ﬂow cytometry analysis showed that the percentage of
HepG2 apoptosis increased signiﬁcantly. The above results
showed consistently that miR-577 can inhibit cell proliferation
of HepG2 signiﬁcantly and promote the apoptosis.Wnt signaling pathway plays a key role in the occurrence and
development of HCC. Wnt signaling pathway activation leads to
the accumulation of downstream molecule b-catenin in cyto-
plasm and migration to cell nucleus [19]. It complexes with LEF/
TCF to form transcription regulation and promotes the
transcription of cyclinD1, c-myc and MMP7 that related to
multiple downstream tumor proliferation as well as invasion,
and eventually led to tumor growth and metastasis [20].
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of the downstream potential biological targets of miR-577. To
study the regulating effect of b-catenin in miR-577 of HCC, we
ﬁrstly detected the protein expression of downstream in the
potential target of b-catenin at histological level. The results
showed that there was a negative correlation between miR-577
and b-catenin protein expression. We then overexpressed miR-
577 in HepG2 successfully by in vitro transfection method.
Through qRT-PCR and Western-Blot detection, it was found
that after overexpression of miR-577, expression levels of b-
catenin mRNA and protein in HepG2 down-regulated signiﬁ-
cantly. Molecular targeted drug used in clinical practice, which
is mainly based on Sorafenib, plays an important role in the
treatment of HCC. Recent researches have conﬁrmed that the
overexpression and intranuclear metastasis of b-catenin in HCC
cells is one of the important reasons to promote HCC cell pro-
liferation and Sorafenib treatment resistance [21]. Therefore, the
negative regulation of miR-577 on b-catenin expression, which
is conﬁrmed by the present study, may have the important
clinical value to ameliorate the treatment and prognosis of
Sorafenib resistant patients.
In conclusion, expression of miR-577 in HCC issues down-
regulated signiﬁcantly, and low expression of miR-577 was
closely related to malignant clinicopathological features of HCC.
miR-577 may inhibit the HCC cell growth through down-
regulating the expression of b-catenin. Hence, miR-577 has a
certain development potential in the diagnosis and biological
target therapy of HCC.
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